

associated with hematopoietic malignancies of lymphoid, myeloid, and erythroid lineage. Additionally, strikingly increased expression of notch-1 has been documented in a number of human tumors including cervical cancer, colon tumors, lung tumors, and pre-neoplastic lesions of the uterine cervix.

Notch antisense oligonucleotides (or other molecules that interfere with the expression or function of notch) could be therapeutically administered to treat or prevent tumors. It has not been found that administration of notch antisense oligonucleotides alone is effective as an anti-neoplastic treatment. The present invention has overcome this problem by combining the administration of a cell differentiation agent with an antibody that antagonizes the function of a notch protein and hence interferes with the expression or function of a notch protein (such as the notch-1 protein). This combination of approaches has unexpectedly been found to induce apoptosis in neoplastic cells, and provide a useful therapeutic application of this technology.

In particular the tumor cell is one that is characterized by increased activity or increased expression of a notch protein, such as a notch-1 or notch-2 protein. Examples of tumor types that over express notch-1 include cervical cancer, breast cancer, colon cancer, melanoma, seminoma, lung cancer and hematopoietic malignancies, such as erythroid leukemia, myeloid leukemia, (such as chronic or acute myelogenous leukemia), neuroblastoma and medulloblastoma. The differentiation inducing agent to which the cell is exposed can be selected from a broad variety of agents, including retinoids, polar compounds (such as hexamethylene bisacetanamide), short chain fatty acids, organic acids, Vitamin D derivatives, cyclooxygenase inhibitors, arachidonate metabolism inhibitors, ceramides, diacylglycerol, cyclic nucleotide derivatives, hormones, hormone antagonists, biologic promoters of differentiation, and derivatives of any of these agents.

Technology

This invention provides compositions, pharmaceutical compositions, and methods for stimulating/increasing cell differentiation, and is particularly related to the treatment of tumors which have increased notch-1 expression. A polyclonal and/or monoclonal antibody generated against human Notch-1 Epidermal Growth Factor ("EGF") that recognizes an extracellular epitope of notch-1 and that stimulates target cell

differentiation in the presence of an effect amount of differentiation inducing agent is disclosed as is the hybridoma which produces these antibodies. At a time during which differentiation has been promoted, and the cell is susceptible to interference with the anti-apoptosis effect of notch, the function of the notch protein is disrupted. Disruption of notch function can be achieved, for example, by the expression of antisense oligonucleotides that specifically interfere with expression of the notch protein on the cell, or by monoclonal antibodies that specifically bind to notch and inactivate it. This technology represents a novel method to induce apoptosis in tumor cells.

The above mentioned Invention is available, including any available foreign intellectual property rights, for licensing.

Dated: November 24, 1999.

Jack Spiegel,

Director, Division of Technology Development & Transfer, Office of Technology Transfer.

[FR Doc. 99-31343 Filed 12-2-99; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel. ZDK1 GRB-7 J3 P.

Date: December 6-8, 1999.

Time: 7:00 p.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Radisson Hotel at Gateway, 651 Huron Road, Cleveland, OH 44115.

Contact Person: Lakshmanan Sankaran, Scientific Review Administrator, Review Branch, DEA, NIDDK, Natcher Building

Room 6AS25F, National Institutes of Health, Bethesda, MD 20892-6600, (301) 594-7799.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel. ZDK1 GRB C (J1).

Date: December 7-9, 1999.

Time: 7:30 p.m. to 11:00 a.m.

Agenda: To review and evaluate grant applications.

Place: New Haven Hotel, 229 George Street, New Haven, CT 06510.

Contact Person: Dan E. Matsumoto, Scientific Review Administrator, Review Branch, DEA, NIDDK, Natcher Building Room 6AS37B, National Institutes of Health, Bethesda, MD 20892-6600, (301) 594-8894.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel. ZDK1 GRB-C J3 P.

Date: December 16-18, 1999.

Time: 7:00 p.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn, 5 Blossom Street, Boston, MA 02114.

Contact Person: Dan E. Matsumoto, Scientific Review Administrator, Review Branch, DEA, NIDDK, Natcher Building Room 6AS37B, National Institutes of Health, Bethesda, MD 20892-6600, (301) 594-8894.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: November 24, 1999.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 99-31340 Filed 12-2-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Disease; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose

confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel. ZDK1 GRB-D (C4).

Date: November 29, 1999.

Time: 3:30 PM to 5:30 PM.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, Natcher Bldg., 45 Center Drive, Room 6AS-37, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Ann A. Hagan, Chief, Review Branch National Institute of Diabetes, Digestive and Kidney Diseases National Institutes of Health, PHS, DHHS Rm. 6AS37, Bldg., 45 Bethesda, MD 20892 (301) 594-8886.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: November 24, 1999.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 99-31341 Filed 12-2-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4444-N-10]

Notice of Proposed Information Collection: Evaluation of Low-Level Lead Hazard Intervention in the CLEARCorps Program

AGENCY: Office of Lead Hazard Control, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: *Comments Due Date:* February 1, 2000.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB

Control Number and should be sent to: Gail N. Ward, Reports Liaison Officer, Department of Housing and Urban Development, 451 7th Street, SW., Room P3206, Washington, DC 20410.

FOR FURTHER INFORMATION CONTACT: Mr. Eugene Pinzer, (202) 755-1785 ext. 120 (this is not a toll-free number) for available documents regarding this proposal.

SUPPLEMENTARY INFORMATION: The Department is submitting the proposed information collection to OMB for review, as required by the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35, as amended).

This Notice is soliciting comments from members of the public and affected agencies concerning the proposed collection of information to: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the Department's estimate of the burden of the proposed collection of information; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond; including through the use of appropriate automated collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

This Notice also lists the following information:

Title of the Proposal: Evaluation of Low-Level Lead Hazard Intervention in the CLEARCorps Program.

OMB Control Number: To be assigned.

Need For the Information and

Proposed Use: Various means of treating residential lead-based paint hazards have been developed to reduce or eliminate the potential that occupants could be overexposed to lead.

CLEARCorps, a division of AmeriCorps, has been funded by Congress, through HUD, to perform "low-level lead hazard interventions." Plans include

CLEARCorps operation in four cities: Baltimore, Detroit, Pittsburgh, and Portland, OR. Low level interventions are designed to reduce dust levels and prevent ingestion of lead-containing dust by infants and young children. Low-level interventions do not typically include lead-based paint removal. The CLEARCorps program for low-level interventions will be evaluated by the National Center for Lead Safe Housing and by Quantech, both funded by HUD.

The HUD Guidelines or the Evaluation and Control of Lead-Based Paint Hazards in Housing

("Guidelines") recommend that, "unless precluded by regulation, inert controls are most easily implemented when most surfaces with lead-based paint are intact and structurally sound and lead exposure comes primarily from deteriorating paint and excessive levels of lead in household dust and/or soil. Interim controls are also appropriate if the Housing unit is slated for demolition or renovation within a few years. In many cases resources will not be available to finance permanent abatement, making interim controls the only feasible approach." There is considerable interest regarding the use of this potentially cost-effective treatment.

This information collection will involve telephone interviews and visits to CLEARCorps sites in the selected cities, as well as telephone interviews and visits to homes where the low-level interventions will be performed. If appropriate, the results of this information collection will be used to improve existing HUD guidance on the use of low-level lead-based paint interventions; findings may also be used to determine the need for and to design a study of the short and long term effectiveness of low-level lead-based paint interventions in controlling lead-based paint hazards.

Agency Form Numbers: None.

Members of Affected Public: Owners and occupants of units where low-level interventions will be performed.

Total Burden Estimate (First Year)

Number of respondents: 180

Frequency of response: 19

Total Hours of response: 652

Status of the proposed information collection: New collection.

Authority: The Paperwork Reduction Act of 1995, 44 U.S.C. Chapter 35, as amended.

Dated: November 23, 1999.

David E. Jacobs,

Director, Office of Lead Hazard Control.

[FR Doc. 99-31441 Filed 12-2-99; 8:45 am]

BILLING CODE 4210-01-M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4432-N-48]

Federal Property Suitable as Facilities to Assist the Homeless

AGENCY: Office of the Assistant Secretary for Community Planning and Development, HUD.

ACTION: Notice.

SUMMARY: This Notice identifies unutilized, underutilized, excess, and